Global Schizophrenia Disease Coverage to 2024 - Pipeline, Marketed Drugs, Epidemiology, Treatment & Forecasts Analysis - ResearchAndMarkets.com

DUBLIN--()--The "Schizophrenia Disease Coverage to 2024" report has been added to ResearchAndMarkets.com's offering.

While available antipsychotics already alleviate schizophrenia's positive symptoms, no drug has been shown to adequately address negative or cognitive symptoms. The lack of effective treatment options creates opportunities for drug developers, and leaves room for the future growth of the schizophrenia market.

Recent events and opinion

  • The blockbuster antipsychotic era is coming to an end - the absence of true innovation in product development means that the pipeline is failing to yield novel therapies which will be able to attain blockbuster status.
  • The reformulation of oral antipsychotics into long-acting depots has extended the longevity of antipsychotic franchises. Abilify Maintena (aripiprazole; Otsuka/Lundbeck) and Invega Sustenna/Trinza (paliperidone palmitate; Johnson & Johnson) are two notable examples of this strategy. Their increasing sales could help dampen the effects of market contraction due to the genericization of oral brands.
  • Compliance continues to represent a notable barrier to positive treatment outcomes, as does the failure of current therapies to improve the negative and cognitive symptoms of schizophrenia. New treatments that target these hard-to-treat symptoms will provide sufficient differentiation to attain commercial success.

Key Topics Covered:

Forecast: Schizophrenia

  • Executive Summary
  • Market Overview and Trends
  • Methodology and Market Definition
  • Abilify (Aripiprazole)
  • Abilify Maintena (Aripiprazole)
  • ALKS 3831 (Olanzapine/Samidorphan)
  • Aristada (Aripiprazole Lauroxil)
  • Invega Sustenna/Trinza (Paliperidone Palmitate)
  • Latuda (Lurasidone)
  • Lonasen (Blonanserin)
  • Rexulti (Brexpiprazole)
  • Risperdal Consta (Risperidone)
  • Saphris (Asenapine)
  • Seroquel/Seroquel XR (Quetiapine Fumarate)
  • Vraylar (Cariprazine)
  • Primary Research Methodology

Treatment: Schizophrenia (Published on 30 November 2017)

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Treatment Dynamics
  • UNMET Needs in Schizophrenia


Epidemiology: Schizophrenia

  • Executive Summary
  • Disease Background
  • Methodology
  • Forecast
  • Epidemiologist Insight
  • Bibliography
  • Appendix: Additional Sources

Marketed Drugs: Schizophrenia

  • Executive Summary
  • Product Overview
  • Product Profile: Abilify
  • Product Profile: Abilify Maintena
  • Product Profile: Aristada
  • Product Profile: Invega Sustenna/Trinza
  • Product Profile: Latuda
  • Product Profile: Rexulti
  • Product Profile: Risperdal Consta
  • Product Profile: Saphris
  • Product Profile: Seroquel/Seroquel XR
  • Product Profile: Vraylar
  • Product Profile: Zyprexa

Pipeline: Schizophrenia

  • Executive Summary
  • Clinical Pipeline Overview
  • Comparator Therapy
  • Recently Discontinued Drugs
  • Product Profile (Late Stage): ALKS 3831
  • Product Profile (Late Stage): ITI-007

For more information about this report visit https://www.researchandmarkets.com/research/cmcbxb/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Schizophrenia Drugs